Culture	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
(	O
SARS-CoV-2	O
;	O
f.2019-nCoV	O
)	O

Cell	O
culture	O
tubes	O
were	O
moved	O
from	O
the	O
37	O
C	O
incubator	O
to	O
a	O
Class	O
II	O
Biosafety	O
cabinet	O
,	O
within	O
a	O
PC3	O
laboratory	O
environment	O
.	O

Growth	O
medium	O
from	O
previously	O
prepared	O
Vero	O
E6	O
tubes	O
was	O
discarded	O
to	O
waste	O
.	O

Clinical	O
samples	O
were	O
prepared	O
by	O
diluting	O
in	O
Opti-Mem	O
reduced	O
serum	O
growth	O
medium	O
without	O
foetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
and	O
filtering	O
through	O
a	O
0.2	O
M	O
,	O
13	O
mm	O
Acrodisc	O
filter	O
(	O
Bio-Strategy	O
Laboratory	O
Products	O
,	O
Australia	O
)	O
.	O

150-200	O
L	O
of	O
filtered	O
patient	O
material	O
was	O
inoculated	O
onto	O
separate	O
confluent	O
cell	O
monolayers	O
along	O
with	O
a	O
negative	O
control	O
tube	O
(	O
150-200	O
L	O
of	O
Opti-Mem	O
alone	O
)	O
.	O

NOTE	O
:	O
Fresh	O
specimens	O
are	O
best	O
for	O
succesful	O
viral	O
culture	O
.	O

Samples	O
were	O
absorbed	O
onto	O
cells	O
by	O
incubating	O
tubes	O
for	O
1	O
hr	O
at	O
37	O
C	O
before	O
cultures	O
were	O
re-fed	O
with	O
2	O
mL	O
of	O
pre-warmed	O
(	O
37	O
C	O
)	O
Opti-Mem	O
reduced	O
serum	O
growth	O
medium	O
.	O

NOTE	O
:	O
It	O
can	O
be	O
informative	O
to	O
collect	O
a	O
200	O
L	O
sample	O
at	O
this	O
point	O
as	O
a	O
Day	O
0	O
value	O
to	O
test	O
alongside	O
other	O
culture	O
samples	O
from	O
Day	O
2	O
onwards	O
.	O

Cultures	O
were	O
incubated	O
for	O
2-7	O
days	O
until	O
signs	O
of	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
was	O
observed	O
.	O

In	O
our	O
hands	O
,	O
cultures	O
that	O
were	O
inoculated	O
with	O
patient	O
sample	O
extracts	O
which	O
,	O
at	O
original	O
testing	O
produced	O
CTs	O
of	O
approximately	O
20	O
cycles	O
,	O
developed	O
signs	O
of	O
CPE	O
within	O
3	O
days	O
post-inoculation	O
.	O

In	O
the	O
event	O
low-levels	O
of	O
the	O
virus	O
were	O
not	O
detected	O
by	O
observation	O
of	O
CPE	O
in	O
the	O
first	O
isolation	O
attempt	O
,	O
negative	O
cell	O
culture	O
supernatants	O
should	O
be	O
further	O
passaged	O
onto	O
fresh	O
Vero	O
E6	O
monolayers	O
up	O
to	O
3	O
times	O
with	O
testing	O
as	O
described	O
in	O
Step	O
6	O
.	O

A	O
cell	O
culture	O
is	O
suspected	O
of	O
hosting	O
virus	O
replication	O
based	O
on	O
the	O
presence	O
of	O
CPE	O
including	O
damage	O
to	O
the	O
monolayer	O
,	O
cell-clearing	O
and	O
morphological	O
changes	O
.	O

Suspected	O
cultures	O
were	O
further	O
confirmed	O
using	O
the	O
Corman	O
et	O
al	O
.	O
E	O
E	O
and	O
Northill	O
et	O
al	O
.	O

ORF1ab	O
ORF1ab	O
novel	O
coronavirus	O
reverse-transcription	O
real-time	O
polymerase	O
chain	O
reaction	O
(	O
RT-rPCRs	O
)	O
tests	O
.	O

Samples	O
taken	O
from	O
a	O
suspected	O
culture	O
are	O
expected	O
to	O
contain	O
levels	O
of	O
virus	O
that	O
exceed	O
those	O
present	O
in	O
the	O
original	O
clinical	O
sample	O
so	O
we	O
would	O
expect	O
to	O
see	O
CT	O
values	O
lower	O
than	O
those	O
obtained	O
from	O
testing	O
the	O
original	O
clinical	O
sample	O
extract	O
by	O
RT-rPCRs	O
.	O

SLOW	O
CULTURES	O
:	O
If	O
the	O
CT	O
value	O
from	O
an	O
extract	O
of	O
the	O
first	O
passage	O
of	O
a	O
SARS-CoV-2	O
culture	O
is	O
the	O
same	O
or	O
higher	O
(	O
suggesting	O
a	O
lower	O
viral	O
load	O
)	O
than	O
the	O
CT	O
value	O
from	O
the	O
RT-rPCR	O
of	O
the	O
original	O
clinical	O
sample	O
,	O
further	O
investigation	O
will	O
be	O
required	O
to	O
ensure	O
the	O
culture	O
has	O
biologically	O
amplified	O
virus	O
.	O

Consideration	O
should	O
be	O
given	O
to	O
whether	O
such	O
a	O
result	O
is	O
due	O
to	O
the	O
detection	O
of	O
viral	O
remnants	O
from	O
the	O
inoculum	O
rather	O
than	O
virus	O
amplification	O
.	O



